GM CSF Mouse

  • Name
  • Description
  • Pricings
  • Quantity
  • GM CSF Mouse
  • Granulocyte Macrophage-Colony Stimulating Factor Mouse Recombinant
  • Shipped at Room temp.

Catalogue number



CSF-2, MGI-1GM, GM-CSF, Pluripoietin-alpha, Molgramostin, Sargramostim.


GMCSF is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The active form of the protein is found extracellularly as a homodimer. This gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13.
GM-CSF stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.


Granulocyte Macrophage Colony Stimulating Factor Mouse Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 125 amino acids and having a molecular mass of 14285.35 Dalton.
GM-CSF Mouse is purified by proprietary chromatographic techniques.


Escherichia Coli.

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.


GM-CSF Mouse was lyophilized with no additives.


It is recommended to reconstitute the lyophilized Granulocyte Macrophage Colony Stimulating Factor in sterile 20mM AcOH (acetic Acid) not less than 100µg/ml, which can then be further diluted to other aqueous solutions.


Lyophilized Granulocyte Macrophage Colony Stimulating Factor although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution GM-CSF should be stored at 4°C between 2-7 days and for future use below -18°C.
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please prevent freeze-thaw cycles.


Greater than 98.0% as determined by(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.

Amino acid sequence

The sequence of the first five N-terminal amino acids was determined and was found to be Met-Ala-Pro-Thr-Arg.

Biological Activity

The ED50 as determined by the dose-dependant stimulation of the proliferation of murine FDC-P1 cell line is < 0.2 ng/ml, corresponding to a Specific Activity of 5,000,000 IU/mg.

Protein content

GM-CSF quantitation was carried out by two independent methods
1. UV spectroscopy at 280 nm using the absorbency value of 0.765 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).

2. Analysis by RP-HPLC, using a calibrated solution of GM-CSF as a Reference Standard.


1.Title:Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery.
Publication: Mol Ther. 2005 Dec;12(6):1197-205. Epub 2005 Aug 22. PMID: 16112909
Applications: The Mouse GM-CSF used for 2 purposes:
1. As an adjuvant for DNA vaccine which included seven plasmids encoding nine HIV-1 proteins. The mice were injected with the DNA vaccine together with recombinant mouse GM-CSF. 2. Used in Elisa.

2.Title: Neospora caninum: cloning and expression of a gene coding for cytokine-inducing profilin. 
Publication: Exp Parasitol. 2010 Aug;125(4):357-62. Epub 2010 Mar 6. PMID: 20211619
Applications: Used for immunoblotting

3.Title: Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: Antimicrob Agents Chemother. 2008 February; 52(2): 716–718.
Published online 2007 November 5
Applications: GM-CSF as tested a therapeutic potential in a murine model of pulmonary aspergillosis. In summary, this pilot study indicates that GM-CSF administered intranasally may be a novel therapeutic approach for the prevention or treatment of pulmonary fungal infections and may augment the efficacies of antifungal agents.
GM-CSF was given intranasal.

4.Title: Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
Publication: The Journal of Immunology February 1, 2009 vol. 182 no. 3 1667-1673

5.Title:Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer.
Publication:Article first published online: 21 JUN 2007 DOI:10.1111/j.1365-3083.2007.01945.x
Scandinavian Journal of Immunology Volume 66, Issue 1, pages 43–51, July 2007

6.Title:Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis.
Publication: First published November 2007, doi: 10.1128/?AAC.00760-07 Antimicrob. Agents Chemother. February 2008 vol. 52 no. 2 716-718

7. Title: O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma.
Publications:  Clinical & Experimental Immunology 143.1 (2006): 139-149.

8. Title: Novel Functions of Herbal Medicines in DendriticCells: Role of Amomi Semen in Tumor Immunity
Publications:  Microbiology and immunology 51.11 (2007): 1121-1133.

9. Title: The Herbal Medicine Compound Falcarindiol from Notopterygii Rhizoma Suppresses Dendritic Cell Maturation
Publication:  Journal of Pharmacology and Experimental Therapeutics 333.3 (2010): 954-960.


ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Back to Top